Mcmillion Capital Management Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,948 shares of the company’s stock after selling 577 shares during the period. Johnson & Johnson makes up approximately 2.7% of Mcmillion Capital Management Inc.’s portfolio, making the stock its 9th biggest holding. Mcmillion Capital Management Inc.’s holdings in Johnson & Johnson were worth $4,607,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of JNJ. Enterprise Financial Services Corp increased its stake in Johnson & Johnson by 2.4% during the 4th quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock worth $2,106,000 after buying an additional 358 shares during the period. Welch Investments LLC increased its stake in Johnson & Johnson by 1.0% during the 4th quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock worth $5,027,000 after buying an additional 373 shares during the period. YHB Investment Advisors Inc. increased its stake in Johnson & Johnson by 0.5% during the 4th quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock worth $10,693,000 after buying an additional 381 shares during the period. Franklin Parlapiano Turner & Welch LLC increased its stake in Johnson & Johnson by 1.0% during the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock worth $5,363,000 after buying an additional 382 shares during the period. Finally, Regent Investment Management LLC increased its stake in Johnson & Johnson by 0.8% during the 4th quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock worth $6,591,000 after buying an additional 385 shares during the period. 65.97% of the stock is currently owned by institutional investors.
NYSE JNJ opened at $121.34 on Monday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $325.54 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 1.86 and a beta of 0.73.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th were issued a $0.90 dividend. The ex-dividend date of this dividend was Friday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 49.32%.
Several research firms recently issued reports on JNJ. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Wednesday, April 18th. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price target on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target on the stock in a research note on Wednesday, April 11th. Jefferies Financial Group set a $161.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, March 23rd. Finally, Citigroup decreased their price objective on shares of Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating for the company in a report on Monday, April 23rd. Six equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $141.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.